Dechert Advises DNA Script on the Extension of its Series B Financing
Dechert advised DNA Script, the global leader in enzymatic DNA synthesis, in connection with the extension of its Series B financing for nearly €46 million. Dechert previously advised DNA Script in the first €35 million round of financing in May 2019, bringing the total amount of the transaction to approximately €80 million.
Existing investors Illumina Ventures, Merck Ventures, Life Sciences Partners (LSP), Bpifrance Large Venture and Danaher Life Sciences are participating in this fundraising round, alongside new investors Casdin Capital, Agilent Technologies and Alexandria Real Estate.
The financing will allow DNA Script to strengthen its workforce to accelerate research and development of new products and to prepare for the product launch of its DNA sequencing printer on the American and European markets.
The Dechert team advising DNA Script included partner Anne-Charlotte Rivière and associate Claire Tanguy.
About Dechert
Dechert is a leading global law firm with 26 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for all clients.
